Skip to main content

Stefan Bjelosevic, PhD

Boston, MA
United States

Dana-Farber Cancer Institute

I am a Postdoctoral Fellow with a strong background in malignant hematology research. My work focusses on identifying targetable metabolic vulnerabilities in aggressive leukemias in which effective treatment regimens are limited. I completed my PhD under the mentorship of Professor Ricky Johnstone at the Peter MacCallum Cancer Centre in Melbourne, Australia, where I discovered that FLT3-ITD mutations, among the most common in acute myeloid leukemia (AML), promote the biosynthesis of the amino acid serine. Genetic or pharmacological ablation of serine biosynthesis was selectively lethal to FLT3-ITD-mutant AML cells and synergized with cytarabine, the standard of care chemotherapy agent. This work was published in Cancer Discovery in 2021. My postdoctoral work unifies and builds on my interests and expertise in AML model generation and characterization, large-scale genetic screening, transcription, epigenetics, cellular metabolism, and use of in vivo models for therapeutic validation.

Program Name(s)
Career Development Program
Dr. Bjelosevic